Technical Analysis for SVRA - Savara, Inc.

Grade Last Price % Change Price Change
grade D 12.68 6.20% 0.74
SVRA closed up 6.2 percent on Thursday, January 18, 2018, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
10 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Down Down
See historical SVRA trend table...

Date Alert Name Type % Chg
Jan 18 Lower Bollinger Band Walk Weakness 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Lower Bollinger Band Touch Weakness 0.00%
Jan 18 Oversold Stochastic Weakness 0.00%
Jan 17 Hammer Candlestick Bullish 6.20%
Jan 17 Lower Bollinger Band Walk Weakness 6.20%
Jan 17 Wide Bands Range Expansion 6.20%
Jan 17 Lower Bollinger Band Touch Weakness 6.20%
Jan 17 Oversold Stochastic Weakness 6.20%
Jan 16 Fell Below 50 DMA Bearish 3.85%

Older signals for SVRA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
Is SVRA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 17.19
52 Week Low 4.6
Average Volume 186,511
200-Day Moving Average 8.6077
50-Day Moving Average 13.1518
20-Day Moving Average 14.456
10-Day Moving Average 13.359
Average True Range 0.8227
ADX 34.07
+DI 17.42
-DI 34.66
Chandelier Exit (Long, 3 ATRs ) 14.7219
Chandelier Exit (Short, 3 ATRs ) 13.8181
Upper Bollinger Band 17.2304
Lower Bollinger Band 11.6816
Percent B (%b) 0.18
BandWidth 38.384062
MACD Line -0.3204
MACD Signal Line 0.0951
MACD Histogram -0.4155
Fundamentals Value
Market Cap 306.9 Million
Num Shares 24.2 Million
EPS -3.50
Price-to-Earnings (P/E) Ratio -3.62
Price-to-Sales 526.42
Price-to-Book 2.64
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.40
Resistance 3 (R3) 14.25 13.53 14.11
Resistance 2 (R2) 13.53 13.09 13.60 14.02
Resistance 1 (R1) 13.10 12.82 13.32 13.25 13.92
Pivot Point 12.38 12.38 12.49 12.46 12.38
Support 1 (S1) 11.96 11.94 12.17 12.11 11.44
Support 2 (S2) 11.24 11.67 11.31 11.34
Support 3 (S3) 10.81 11.24 11.25
Support 4 (S4) 10.96